Elemental impurity risk management can help biomanufacturers to maintain regulatory alignment and ensure patient safety.
Downstream bioprocessing steps have long been a challenge to drug manufacturers, particularly the chromatography step for purification of monoclonal antibodies (mAbs). The complexity of traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback